top of page

Marc Hertz, PhD, CEO of GRI Bio underscores importance of the interim data from their ongoing Phase 2a biomarker study for Idiopathic Pulmonary Fibrosis (IPF) 

Access, Ideas, Clarity

A leading virtual platform providing investors with direct access to innovative companies, management teams and thought leaders

Contat Us
bottom of page